🔗 Share this article

As the United States continues making historic adjustments to its vaccination recommendations, a particular individual has surfaced unexpectedly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by casting doubt on coronavirus shots in the global health crisis and has concentrated on alleged fatalities after Covid vaccination in her recent position at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Schedule

Agency leaders planned to reveal sweeping revisions to the childhood vaccination calendar in December, synchronizing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US at odds with many the global community with little proof for benefit. The announcement has been pushed back until the new year.

Instead of the top vaccines chief, Høeg is listed to speak at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this calendar year.

A New Direction at the Regulatory Body

The acting appointment could signify a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a greater focus upon rolling back previously authorized vaccines at the FDA.

The new acting director has repeatedly called for ending certain pediatric vaccine recommendations in the US so as to align more like the Danish model, a society with nationalized medicine and a population roughly the population of the state of Wisconsin.

So far comments, she has kept her attention on immunizations – typically the responsibility of Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Questions Over Qualifications

Dr. Høeg has little discernible experience in pharmaceutical research, regulation or administrative roles, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She appears not to have any of the qualifications” for leading the drug-regulation department, said Jonathan Howard. “She’s never run a scientific study. She lacks experience in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Former commissioners of CBER would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that previous people who led the center have had.”

This division has an vast portfolio at the FDA, the former commissioner emphasized.

“Many people just zeroes in on the innovative therapies, but the off-patent medication office approves thousands of generic medications. There’s a biosimilars division, OTC medication office and more, and all of those have to be supervised,” Woodcock said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a significant leadership element to the role, which supervises more than 5,000 personnel. “It’s a enormous leadership role, if you perform it correctly,” the former official added.

Response and Contentious Initiatives

When asked about questions about Dr. Høeg's qualifications and whether this appointment represents increased cooperation among FDA leaders on immunizations, a representative responded that the “concerns are based on inaccurate presumptions”.

“Her resume matches the functions of her role,” the representative said, noting the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg inherits the commissioner’s new expedited review system, a disputed expedited drug-approval program that apparently troubled her former heads. “How are these medications being picked for this expedited pathway? Who is making the calls?” Howard said. “There is a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he said, “the agency looks to be trending towards less stringent oversight of most medications, except for immunizations.”

Documented Past Work on Immunizations

Regarding immunizations, Høeg has a more established, if concerning, past, Howard said. She published a analysis using non-validated public submissions to determine the incidence of heart inflammation following COVID-19 vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the new government encompassed changing regulations for novel immunizations and discontinuing “non-essential” vaccines, she stated following the vote on a online show. At the agency, Dr. Høeg has according to sources floated the idea of barring teenage boys from getting Covid vaccines.

“She is an thorough ideologue who commences with her conclusions and reverse-engineers to accommodate the evidence in a highly deceptive, untruthful manner,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other contrarians, {like|